NEW BRUNSWICK, N.J., Aug. 3, 2011 /PRNewswire-USNewswire/ -- A new diagnostic test for Alzheimer's disease (AD) developed by biotech company Durin Technologies in New Jersey has shown promising results using antibody biomarkers in a drop of blood to identify presence of the disease, according to findings that appear online in PLoS ONE.
The research was made possible through an investment by Foundation Venture Capital Group (FVCG), LLC, a New Jersey Health Foundation affiliate that invests in start-up companies founded by researchers at the University of Medicine and Dentistry of New Jersey.
"This research is an exciting step in AD diagnosis that seems extremely promising based on preliminary results," said James M. Golubieski, president of Foundation Venture Capital Group. "If, after further study, Dr. Nagele's research bears out, his success could help ease the suffering of millions of people worldwide as they struggle with this devastating illness."
Dr. Robert Nagele, founder of Durin Technologies and a researcher at the New Jersey Institute for Successful Aging at the UMDNJ-School of Osteopathic Medicine in Stratford, NJ, focuses his efforts on the concept that autoantibodies are involved in the degenerative mechanism of AD.
Study results published in PLoS ONE show the test, which uses microarray technology to analyze a small sample of blood, has a diagnostic sensitivity of 96 percent and a specificity of 92.5 percent and may be able to detect the disease even in its earliest stages, years before symptoms such as memory loss, poor judgment or erratic behavior appear.
"There's a dire need for an accurate, relatively non-invasive and inexpensive diagnostic test for AD," explained Dr. Nagele. "A test that can detect the disease years before symptoms appear would make early intervention possible, a significant breakthrough as pharmaceutical companies are now working feverishly to develop new drug
|SOURCE New Jersey Health Foundation|
Copyright©2010 PR Newswire.
All rights reserved